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Abstract
Background: Bone remodeling, insulin levels and fat mass interrelationship 
in glucose homeostasis control was evaluated in Weaning Normal (W) and 
Obese (O) rats fed High (H), Normal (N) or Low (L) Ca intakes.
Methods: Glucose, Cholesterol (Chol), HDL-Chol, Triglyceride (TGL), Ca, P, 
insulin, Osteocalcin (OCN) and collagen C-telopeptide (CTX), body composition, 
BMD, BMC, body Ca and P content, perigonadal plus retroperitoneal fat 
(PG+RP) and liver weight were determined and HOMA-IR calculated.
Results: WHCa reached the highest body fat, PG+RP and the highest CTX 
levels (p<0.05); WNCa had the lowest liver weight. WLCa reached the lowest 
body protein content (p<0.05) and the highest glucose, insulin and HOMA-IR 
(p<0.05). WLCa and WHCa had similar Chol levels but higher than WNCa; 
TGL increased and OCN decreased as dietary Ca content increased (p<0.05). 
OLCa presented the highest body fat, Chol and OCN levels but the lowest HDL-
Chol levels (p<0.05); ONCa had the highest body protein percentage (p<0.05). 
OHCa had the lowest CTX levels (p<0.05). PG+RP, liver weight, glucose, insulin 
and HOMA-IR decreased as dietary Ca content increased (p<0.05). O groups 
reached higher adipose PG+RP fat, liver weight, glucose, insulin, Chol, TGL and 
HOMA-IR and lower OCN, CTX and body protein content than their matched-W 
groups (p<0.05).
Conclusion: The relative amount of dietary Ca to P may regulate energy 
metabolism and bone turnover, insulin and body fat interplay in glucose 
homeostasis control. However, the mechanisms differ in physiological conditions 
or in the presence of metabolic abnormalities of energy dysregulation such as 
obesity and T2-diabetes.
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through the interplay between bone, fat tissue and pancreas. 
According to literature, these organs maintain glucose homeostasis 
through the interaction between bone turnover markers, insulin and 
leptin levels.
Osteocalcin (OCN) is a non-collagenous protein secreted 
by osteoblasts/osteocytes. The negative charge of Gamma-
carboxyglutamic acid (GLA) residues increases OCN Calcium (Ca)-
binding properties, resulting in an association with hydroxyapatite in 
bone extracellular matrix. In clinical practice, OCN used to be used 
as a bone formation marker and more broadly, of bone remodeling. 
Bone matrix acidification performed by osteoclasts resorbing activity 
induces OCN bioactivation, which loses Ca affinity and is released into 
bloodstream. OCN bioactive form may regulate energy metabolism 
stimulating insulin synthesis and secretion by the pancreatic β cells, 
and insulin sensitivity and glucose utilization in peripheral tissues 
[1]. Transgenic OCN-deficient mice are fat, insulin resistant, glucose 
intolerant, and hyperlipidemic [2]. Ferron et al. demonstrated that 
OCN production and bioavailability are under insulin control [3].
Osteoblastic Insulin Receptor (InsR) is required for osteoblast 
survival, proliferation, and differentiation. Insulin signalling in 
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Introduction
One of the energy metabolism regulations appears to occur 
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osteoblasts regulates Runx2 expression, OCN production and 
decreases the expression of Osteoprotegerin (OPG). The latter 
increases osteoclastic activity. The acidic environment in the 
resorption lacuna increases OCN bioavailability [3]. Many factors 
regulate the positive feedback loop between the osteoblastic insulin 
signalling and OCN in pancreatic β cells.
Leptin plays an essential role on energy metabolism. Leptin 
secretion correlates positively with adipose tissue mass, and thereby it 
monitors overall energy availability. Leptin inhibits insulin secretion 
through a direct effect on pancreatic β cells and induces the indirect 
suppression of insulin signalling in osteoblasts via Central Nervous 
System (CNS) [4]. These observations establish the tight metabolic 
link between osteoblasts, pancreatic β cells and adipocytes Falta el 
punto.
Energy metabolism dysregulation is associated with intracellular 
lipid accumulation and excess of body adipose tissue storage that 
results in several comorbidities [5]. Type 2 Diabetes Mellitus (T2DM) 
is the most significant obesity-associated metabolic disorder, 
characterized by insulin resistance, hyperglycemia, dyslipidemia 
and alterations in hormonal signalling systems both, in CNS and 
peripheral nervous system [6]. Moreover, T2DM patients have an 
increased risk of bone fragility and fractures, regardless of having 
Bone Mineral Density (BMD) increase [7]. One of the main factors 
involved in T2DM-derived bone fragility would be bone quality 
deterioration due to bone turnover suppression [8].
There is no doubt about the negative effect of low Ca Intake (CaI) 
on bone mass. Furthermore, according to literature, it also appears 
to induce energy dysregulation by affecting insulin secretion and 
lipogenesis [9,10]. Our group evidenced the obesogenic effect of Ca 
insufficiency in rats fed a low Ca diet, which presented an increase in 
fat mass accumulation and a negative effect in lipid profile, but these 
alterations were more evident when animals were prone to obesity 
[11]. Moreover, epidemiological studies determined that obesity 
and T2DM incidence was likely to be inversely associated with the 
increase in dietary Ca [12].
The results of our previous paper led us to postulate that Ca 
amount supplied by the diet may mediate, at least in part, glucose 
homeostasis through changes in bone, pancreas and fat mass interplay. 
Besides, abnormalities in insulin secretion, fat mass accumulation 
and bone remodeling because of T2DM could additionally affect 
the possible effect of CaI on energy metabolism. On these bases, 
the present experimental report evaluated in vivo the interaction of 
bone remodeling, insulin levels and fat mass in glucose homeostasis 
in normal Wistar rats and in obese/T2DM rats fed three different 
dietary Ca contents. The results of this interrelationship were also 
compared between the two strains of rats.
Materials and Methods
Diets
Three experimental isocaloric diets were prepared according to 
American Institute of Nutrition Rodent Diets Recommendations 
settled in 1993 (AIN-93G) [13]. Diet composition was identical, except 
for Ca content. Normal Ca diet (NCa) contained 0.5% Ca, providing 
Ca requirement for rodents; High Ca diet (HCa) contained 0.9% 
Ca, exceeding Ca recommendations by 50% and Low Ca diet (LCa) 
contained 0.2% Ca, contributing by 40% of Ca recommendations 
(Table 1).
Animals
Twenty-four male weaning IIMb/β rats were obtained from Lipid 
and Lipoprotein Laboratory, Clinical Biochemistry Department, 
Rosario National University, Argentina. IIMb/β rats develop 
obesity and T2DM from puberty onwards. They were obtained by 
genetic and environmental maladjustment and a high degree of 
inbreeding. Obese rats also develop hypertryacilglyceridemia without 
hypercholesterolemia, and their glucose intolerance progresses to 
T2DM and obesity-related hypertension [14,15]. Twenty-four male 
weaning Wistar rats were obtained from Nutrition and Food Sciences 
Laboratory Department, Pharmacy and Biochemistry Faculty, 
Buenos Aires University, Argentina.
All rats were housed in individual stainless steel cages and 
were maintained on a 12-h-light/-dark cycle in a temperature and 
humidity-controlled room (21±1°C and 55±10%, respectively).
Rats were maintained in keeping with National Institutes of 
Health Guide for Care and Use of Laboratory Animals. Bioethics 
Committees of Universities of Buenos Aires and Rosario approved 
the protocol.
Experimental design
The experimental design was previously published [11]. In brief, 
mothers were fed one of the three experimental diets from pregnancy 
Diet LCa NCa HCa
Energy (Kcal) 395 395 395
Proteins (g)a 17 17 17
Lipids (g)b 7 7 7
Ca-free salts mixture (g)c 3.5 3.5 3.5
Vitamins(g)d 1 1 1
Choline (g)e 0.25 0.25 0.25
Cellulose (g) 5 5 5
Dextrinf to complete 100 g
Calcium (Ca) (g)g 0.2 0.5 0.9
Inorganic phosphorus (g)h 0.4 0.4 0.4
Magnesium (g)h 0.051 0.051 0.051
Table 1: Centesimal composition of the experimental diets (g/100g).
All diets were prepared according to AIN93-G and they only varied in calcium 
content.
aSodium caseinate (Lactoprot GMBH, Germany) containing 85.1% of protein and 
0.095g% of Ca.
bCommercial soy oil. Molinos Rio de la Plata, Argentina. 
cCa-free salts mixture was prepared according to AIN93-G, except for Ca content.
dVitamins was prepared according to AIN-93G that meet rat requirements 
during growth. Manufactured by the Department of Food Science School of 
Biochemistry, University of Buenos Aires (individual components from Sigma, 
Missouri, USA).
eCholine citrate 0.71% (food grade, Anedra, Argentina).
fCorn dextrin from corn refinery, provided by Food SA Argentina was added as 
carbohydrate (fibre) source to achieve 100 g of diet.
gCaCO3 (food grade individual components, Anedra, Argentina), was added to 
obtain the required Ca concentration.
hPotassium phosphate monobasic and magnesium oxide (food grade individual 
components, Anedra, Argentina), were added to obtain the required P and Mg 
concentration, respectively.
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to weaning. Weanig male IIMb/β and Wistar pups (n=8 per group) 
continued feeding their maternal diet until post-natal day 50 (T=50).
Throughout the experimental period, rats were allowed to 
access deionized water and food ad libitum. Food consumption was 
recorded 3 times per week, until the end of the study.
Body Weight (BW) was registered at birth, at weaning (21 days) 
and thereafter twice a week until T=50. Relative capacity of a food 
source to contribute to weight gain, named food efficiency (g/g) was 
calculated according to the equation:
Food efficiency = Total food intake (g)/increase in BW (g).
At T=50, all animals were subjected to a whole-body densitometry 
in vivo under light anesthesia (ketamine hydrochloride 0.1 mg/100g 
BW and acetopromazine maleate 0.1mg/100g BW). Then, fasting 
blood samples were collected from tail vein, followed by sacrifice 
under CO2 inhalation. Perigonadal (PG) and Retroperitoneal (RP) 
fat, and liver were removed and weighed, and body composition was 
determined.
Analytical procedures
Body fat and body protein contains were determined according 
to Association of Official Analytical Chemists methods as previously 
described [16].
Ca in diets, serum and body ashes was determined by atomic 
absorption spectrophotometry. Inorganic Phosphorus (Pi) in serum, 
diets and body ashes were evaluated according to Gomori’s method. 
Glucose, total Cholesterol (Chol), Hight Density Lipoprotein 
Cholesterol (HDL Chol), and Triglyceride (TGL) levels were 
determined by conventional enzymatic methods. Insulin was 
determined by Enzyme Immunoassay (ELISA) (Rat/Mouse Insulin 
Kit, Millipore, Billerica, MA, USA). Insulin resistance degree was 
determined by Insulin Resistance index [HOMA-IR = (insulin × 
glucose)/22.5] [17]. 25 hydroxyvitamin D (25OHD) was assayed by a 
competitive protein binding method (Diasorin, Stillwater, MN, USA), 
9% intra-assay coefficient of variation. Bone alkaline phosphatase 
(b-ALP) was measured by a colorimetric method (Boehringer 
Mannheim, Germany) after bone enzyme isoform precipitation with 
wheat-germ lectin. OCN (ng/mL) and C-terminal Telopeptide of type 
I collagen (CTX) (ng/mL) were measured by ELISA (Rat-osteocalcin 
and Rat-laps, respectively Osteometer BioTech, Herlev, Denmark), 
6% intra-assay variation coefficient. OCN/b-ALP ratio was calculated.
Densitometry
Total skeleton Bone Mineral Content (tsBMC) and Bone Mineral 
Density (tsBMD) were evaluated using a whole body scanner with a 
specifically designed software for small animals (DPX Alpha, Small 
Animal Software, Lunar Radiation Corp. Madison WI), as previously 
described. In brief, all rats were scanned using an identical scan 
procedure. Precision was assessed by measuring one rat five times 
with repositioning between scans, on the same day and on different 
days [18]. Bone Mineral Content (BMC) and BMD coefficients of 
variation were 3.0 and 0.9% respectively.
Statistical methods
Results were expressed as mean ± Standard Error (SE). Data were 
analyzed using 2-way analysis of variance ANOVA, and Bonferroni 
multiple comparisons. The linear association was analyzed by 
Pearson’s correlation coefficients r and multivariate linear regression. 
Statistical analyses were performed using SPSS for Windows 19.0 
(SPSS, Inc. Chicago, IL). A value of P below 0.05 (p<0.05) was 
considered significant.
Results
Effect of feeding different dietary Ca content
Wistar (W) rats: Independently of dietary Ca content, no 
significant differences were observed in BW among W groups, 
neither at weaning nor throughout the experiment. Food efficiency 
showed similar results in the three W groups (Table 2).
WHCa presented the significantly highest BW-adjusted body fat 
and PG+RP (p<0.05), while no significant differences were observed 
between WLCa and WNCa. WNCa presented the significant lowest 
liver weight (p<0.05), while no differences were observed between 
WLCa and WHCa. WLCa presented the lowest BW-adjusted body 
protein content, but only reached statistical significance versus 
WNCa (p<0.05); no significant differences were observed between 
WNCa and WHCa (Table 3).
WLCa presented the significant highest glucose, insulin and 
HOMA-IR levels (p<0.05). These parameters were also significantly 
higher in WHCa vs. WNCa (p<0.05). WLCa and WHCa reached 
similar Chol levels, which were significantly higher than in WNCa 
(p<0.05). No differences in HDL-Chol were observed among groups. 
 OLCa ONCa OHCa WLCa WNCa WHCa 
BW T=21 (g) 50.1±5.5 48.7±6.2 49.0±5.3 44.5±5.8 44.2±3.4 45.5±5.8
BW T=60 (g) 284.6±8.7 235.1±9.1* 243.6±14.1* 197.6±2.6# 192.9±9.0# 199.3±21.8#
Food efficiency (g/g) 3.10±0.30 3.00±0.50 3.30±0.30  3.10±0.30 3.00±0.40 3.00±.03
Total skeleton BMC (g/100g BW) 0.64±0.20 1.44±0.30* 1.27±0.30*,** 0.71±0.30# 1.54±0.30*,# 1.34±0.20*,**,#
Body Ca content % 394±39 640.±20* 720±34*,** 494±34# 850±25*,# 917±55*,**, #
Body Pi content % 310±13 520±27* 532±22* 561±22# 728±30*,# 823±43*,**, #
Body Ca/Pi ratio 1.37±0.03 1.24±0.04* 1.35±0.03** 0.87±0.04# 1.17±0.03*,# 1.13±0.05*, #
Table 2:
Results were expressed as mean±SD (n=8).
Data were analyzed by ANOVA and Bonferroni as a post hoc test.
*p<0.05 O or W groups compared to LCa diet. 
**p<0.05 O or W groups compared to NCa.
#p<0.05 W groups vs. O groups fed the same diet Ca content.
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WHCa reached the significantly highest TGL levels (p<0.05), while 
WNCa had levels significantly higher than WLCa (p<0.05) (Table 
3). WNCa presented the significant lowest ALP levels, while WHCa 
presented a significant lower level than WLCa (p<0.05) (Table 4).
Regardless of the dietary Ca content, no significant differences in 
25OHD (ng/dL) were observed among the three W groups. WLCa 
showed the lowest Ca level and WHCa showed the significant lowest 
Pi level (p<0.05). WNCa presented the significant lowest b-ALP levels 
(p<0.05), while WLCa only showed a tendency to have higher levels 
than WHCa (p=0.055). OCN decreased significantly with the increase 
in dietary Ca content (p<0.05). The OCN/b-ALP ratio decreased 
as dietary Ca content increased, but only WHCa reached statistical 
significance as compared to the other two W groups (p<0.05). WHCa 
had the significant highest CTX (p<0.05), while WLCa only showed a 
tendency to have higher levels than WNCa (p=0.061) (Table 4).
Body Ca and Pi contents increased significantly with the increase 
in dietary Ca content (p<0.05). WLCa showed the significant lowest 
body Ca/Pi ratio and tsBMC (p<0.05), while no significant differences 
were observed between WNCa and WHCa (Table 2).
WNCa showed a significant correlation between OCN and 
glucose levels (r=0.77; p<0.0001); however, this correlation was not 
observed in WLCa or WHCa groups.
IIMb/β obese (O) and diabetic rats: No differences in BW were 
observed at weaning. Thereafter, OLCa presented the significant 
highest BW throughout the entire study (p<0.05), while OHCa group 
presented a tendency to reach higher values than ONCa, at the end 
of the experience (p=0.067). Irrespectively of the dietary Ca content, 
no differences in food efficiency were observed among the three O 
groups studied here (Table 2).
OLCa presented the significant highest BW-adjusted body 
fat (p<0.05), while no differences were observed between ONCa 
and OLCa. PG+RP/BW and liver weight percentage decreased 
significantly as the dietary Ca content increased (p<0.05). OLCa and 
OHCa had similar body protein percentages, which was lower as 
compared to ONCa (p<0.05) (Table 2).
Glucose, insulin and HOMA-IR levels decreased significantly 
as the dietary Ca content increased (p<0.05). OLCa presented the 
significant highest Chol and the significant lowest HDL Chol (p<0.05); 
no significant differences were observed between ONCa and OHCa. 
OHCa presented the significant highest TGL levels (p<0.05), and 
 OLCa ONCa OHCa WLCa WNCa WHCa 
Glucose (g) 252±28 170±15* 148±12*,** 139±9# 97±12*,# 105±7*,**,#
Insulin (mg/dL) 6.87±2.37 4.07±0.81* 1.92±0,7*,** 1.30±0.54# 0.14±0.01*,# 0.44±0.05*,**,#
HOMA-IR 77.6±14.1 32.0±7.5* 10.3±6.1*,** 4.1±0.5# 0.6±0.4*,# 1.3±0.8*,**,#
Chol (mg/dL) 115±11 88±9* 86±11* 68±4# 52±7*,# 71±4**,#
HDL-Chol (mg/dL) 15.1±0.9 28.5±0.3* 27.3±1.8* 28.0±3.4# 27.9±4.6 28.3±3.1
TGL (mg/dL) 287±54 241±35* 332±29*,** 75±4# 86±8*,# 112±10*,**,#
Body protein % of BW 14.8±0.9 17.3±0.5* 15.8±0.5** 18.9±0.4# 20.4±0.7*,# 19.1±0.8#
Body fat % of BW 15.9±0.6 13.7±0.8* 14.2±0.8* 11.7±0.7# 10.8±0.5# 14.3±0.7*,**
PG+RP/BW 4.81±0.04 4.33±0.07* 3.12±0.01*,** 1.16±0.03# 1.24±0.09# 2.70±0.15*,**,#
Liver weight % of BW 5.48±0.04 5.21±0.05* 4.81±0.07*,** 4.21±0.01# 4.09±0.05*,# 4.35±0.11**,#
Table 3:
Results were expressed as mean±SD (n=8).
Data were analyzed by ANOVA and Bonferroni as a post hoc test.
*p<0.05 O or W groups compared to LCa diet.
**p<0.05 O or W groups compared to Nca.
#p<0.05 W groups vs. O groups fed the same diet Ca content.
 OLCa ONCa OHCa WLCa WNCa WHCa 
sCa (mg/dL) 10.8±0.8 10.5±0.3 9.7±0.2*,** 8.3±0.3# 8.6±0.2# 8.9±0.6#
sPi (mg/dL) 8.7±0.2 8.8±0.2 8.8±0.1 8.7±0.1 8.2±0.3 7.7±0.4*,#
b-ALP (IU/L) 107±14 160±4* 115±15** 85.5±7.3# 70.8±2.2*,# 79.7±4.0**,#
Total ALP 895±58 775±53* 750±66* 619±67# 333±38*,# 442±43*,**,#
OCN (µg/mL) 582±44 399±16* 368±26* 917±29# 800±49*,# 730±56**,#
sCTX (mg/mL) 82.1±3.6 79.7±6.1 69.6±7.4*,** 105.9±7.8# 94.0±6.0# 122.8±12.9*,**,#
OCN/b-ALP 5.65±1.12 3.06±0.60* 4.62±1.39*,** 12.8±0.85# 11.72±1.12# 8.01±0.86*,**,#
25OHD (ng/mL) 21.8±2.4 19.0±2.7 20.5±1.1 13.9±2.2# 12.4±2.8# 14.5±1.7#
Table 4:
Results were expressed as mean±SD (n=8).
Data were analyzed by ANOVA and Bonferroni as a post hoc test.
*p<0.05 O or W groups compared to LCa diet.
**p<0.05 O or W groups compared to NCa.
#p<0.05 W groups vs. O groups fed the same diet Ca content.
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OLCa had a significant higher level than ONCa (p<0.05) (Table 3).
No differences in 25OHD or Pi levels were observed, 
independently of the dietary Ca content. OHCa showed the 
significant lowest serum Ca (p<0.05), while no significant differences 
were observed between the remaining two groups. OLCa had the 
significant highest b-ALP and ONCa the significant highest b-ALP 
level (p<0.05); no significant differences in both parameters were 
observed between the two remaining groups. OLCa presented the 
significant highest OCN, while ONCa and OHCa showed similar 
concentrations. ONCa presented the significant lowest OCN/b-ALP 
ratio (p<0.05), while OHCa presented a significant lower ratio than 
OLCa (p<0.05). OHCa presented the significant lowest CTX levels 
(p<0.05), while no significant differences were found between OLCa 
and ONCa (Table 4).
Body Ca content increased significantly as the dietary Ca content 
increased (p<0.05). OLCa presented the significant lowest body Pi 
content (p<0.05); no significant differences were observed between 
ONCa and OHCa. ONCa had the significant lowest body Ca/Pi ratio 
(p<0.05), while no significant differences were observed between 
OLCa and OHCa. OLCa presented the significantly lowest tsBMD 
(p<0.05) while ONCa reached a value significantly higher than OHCa 
(p<0.05) (Table 2).
Independently of the dietary Ca content, OCN and glucose levels 
did not correlate in the three groups of O rats.
Comparative effect of the diet Ca content between both strains 
of rats: Independently of the dietary Ca content, O rats presented a 
higher BW than W rats, but only OLCa vs. WLCa reached statistical 
significance at weaning. At the end of the study, O groups reached a 
significant higher BW than their non-obese counterparts (p<0.05). 
No significant differences in food efficiency were observed between O 
and W groups, in spite of the dietary Ca content (Table 2).
OLCa and ONCa reached a significantly higher BW-adjusted 
body fat than WLCa and WNCa, respectively (p<0.05), while no 
differences were observed between OHCa and WHCa. Independently 
of the dietary Ca content, O groups presented significant higher 
adipose PG plus RP fat pads and liver weight and a significant lower 
body protein content than their matched-W groups (p<0.05) (Table 
3).
Independent of the diet Ca content, O groups presented 
significant higher glucose, insulin, Chol, TGL and HOMA-IR than 
their matching part in WCa groups (p<0.05). OLCa had HDL-Chol 
significantly lower than WLCa, while no differences were found 
between the other two remaining Ca groups (Table 3).
Independently of the dietary Ca content, O rats presented 
significantly higher Ca, 25OHD, total ALP and b-ALP levels than 
their W-counterparts (p<0.05). OHCa presented significantly higher 
Pi levels than WHCa (p<0.05), while no differences were observed 
between the other two remaining groups. Obese rats presented 
significantly lower levels of OCN, CTX and, OCN/b-ALP ratio than 
their corresponding WCa groups (p<0.05) (Table 4).
Irrespectively of the dietary Ca content, total body Ca and Pi 
content were significantly lower and body Ca/Pi ratio was significantly 
higher in O rats than in their corresponding WCa groups (p<0.05). 
WNCa and WHCa presented a tsBMC significantly higher than 
ONCa and OHCa, while OLCa presented a significantly higher value 
than WLCa (p<0.05) (Table 2).
Discussion
The results of the present report strongly suggest that the relative 
amount of dietary Ca and Pi (different Ca/Pi ratio) regulates both, 
energy metabolism and relationship between bone turnover, insulin 
levels and body fat accumulation in glucose homeostasis control. 
However, the impact of diets appears to differ in diabetes and 
obesity versus normal physiological conditions. Such differences 
were determined by comparing ordinary Wistar rats with genetically 
modified rats. The IIMb/β rats were obtained from a high degree of 
inbreeding of Wistar rats [14,15]. For this reason, obese and diabetic 
rats appear to be an optimal energy metabolism dysregulation model 
to evaluate Ca intake effect in the interplay between bone, pancreas 
and fat tissue in glucose homeostasis.
Effect of the normal Ca diet in the interplay between bone 
and body fat for glucose homeostasis regulation
Recent studies suggested that Ca might be important for activity 
of various non-skeletal tissues. Ca modulates fat metabolism and 
many physiological functions related to glucose homeostasis, 
including insulin resistance [9].
WNCa was control group related to physiological conditions and 
nutritional requirements adequacy. Results of this group showed a 
strong association between glucose and OCN levels, suggesting a 
close linkage between bone remodeling, insulin levels and body fat 
mass in glucose homeostatic control. The mechanism responsible 
includes effect of insulin signalling in regulation of glucose uptake and 
osteoblast proliferation rate. Insulin stimulates collagen, b-ALP and 
OCN production and inhibits OPG synthesis, which decreases OPG/
RANKL ratio stimulating osteoclastic activity [19]. Bone resorption 
induces OCN bioactivation and its release into serum from bone 
extracellular matrix [20]. Bioactive OCN, as osteoblastic hormone, 
stimulates pancreas β-cell proliferation, insulin secretion and insulin 
sensitivity, both, in mice and humans [21]. To avoid hypoglycemia, 
fat tissue produces leptin, which blocks osteoblastic insulin signalling 
through CNS [22].
Genetically modified strain of rats used here spontaneously 
develops obesity and insulin resistance. Obese growing rats fed 
normal Ca diet presented hyperglycemia, hyperinsulinemia and 
signs of fatty liver such as an increase in total ALP levels, liver 
weight and abdominal fat [23]. ONCa also showed a low OCN/b-
ALP ratio, that along with abdominal fat excess and lower BMC as 
compared to WNCa rats might account for impairment in osteoblast 
differentiation. Adipose tissue secretes cytokines and fatty acids that 
may have induced differentiation of mesenchymal precursor cells to 
adipocytes, in detriment of osteoblast differentiation [24]. Early stages 
of osteoblast differentiation express b-ALP, while OCN is expressed 
in mature osteoblasts. Then, changes in OCN/b-APL ratio indicate 
osteoblast maturation disorders that. according to literature, may be 
involved in diabetic fracture risk [25].
Previous studies reported that bone turnover correlates inversely 
with fasting insulin and visceral adiposity [26, 27]. In addition, it 
was also suggested that in presence of adiposity, low OCN impairs 
insulin tolerance [28, 29]. These metabolic disarrays were observed in 
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obese rats fed normal Ca diet studied here. Indeed, ONCa presented 
insulin resistance and low bone turnover rate; the latter evidenced 
by lower OCN and CTX than control. Obesity was also associated to 
high Parathormone (PTH) levels, main regulator of bone turnover 
[30]. In the present report, PTH was not evaluated; however, ONCa 
showed higher calcemia than control, suggesting certain degree of 
secondary hyperparathyroidism (2°HPT) that, in presence of low 
bone turnover, seems contradictory. Nonetheless, ONCa also showed 
hyperlipidemia that according to a previous report, could induce PTH 
resistance, independently of 25OHD levels [31]. In this regard, excess 
of fat tissue increases the release of certain cytokines, such as resistin 
which links obesity to T2DM. Resistin is involved in development of 
other resistances than insulin resistance, including leptin and PTH 
resistances [32]. The latter might also contribute to bone turnover 
decrease in ONCa group.
According to the present results, we hypothesized that obesity 
along with insulin resistance and the possible presence of other 
resistances may affect whole-body glucose homeostasis, inducing 
changes in the interplay between bone, pancreas and fat mass. This 
mechanism may explain the lack of association between OCN and 
glycemia levels in ONCa rats.
Effect of the low Ca diet in the interplay between bone and 
body fat in the control of glucose homeostasis
WLCa rats showed a typically pre-diabetic condition, i.e., 
elevated levels of insulin and slight hyperglycemia. They also 
showed a high HOMA-IR index and high hypercholesterolemia 
without hypertriglyceridemia. These signs strongly suggest glucose 
homoeostasis impairment, presence of insulin resistance and a certain 
degree of dyslipidemia. The mechanism responsible for these findings 
is thought to be related to low dietary Ca without changes in Pi 
contain that led to low Ca/Pi ratio, which affects Ca absorption [33]. 
Relative excess of Pi, especially in combination with low Ca intakes, 
may reduce passive shift of Ca by forming insoluble salts in intestinal 
lumen [34]. Low Ca absorption negatively affects bone metabolism 
as evidenced in the present report. Increase in bone turnover could 
be responsible for the bone mass decrease observed in WLCa. In 
addition, low Ca availability may decrease Ca2+ influx to β-cell, 
affecting insulin secretion and signalling, and GLUT-4 activity [35]. 
Insulin secretion impairment leads to hyperglycemia and eventually 
causes diabetes, while glucose transport disability into adipocytes, 
along with inability to suppress cell lipolysis, place hepatocytes under 
great metabolic stresses and favor insulin resistance and T2DM 
development over time [36]. In this regard, some observational and 
control studies have shown an inverse association between Ca status 
and insulin resistance as well as risk of T2DM or Metabolic Syndrome 
(MS) [10]. These changes induced by low Ca intake may explain the 
loss of association between OCN and glucose levels.
WLCa also showed a small accumulation of abdominal and body 
fat and a quite important decrease in lean body mass, suggesting 
the onset of a possible shift in energy away from fat stores. A longer 
period of study would have possibly evidenced higher alterations 
in fat metabolism and obesity, at expenses of impairing protein 
synthesis. It is important to take into account that presence of insulin 
resistance affects carbohydrates, lipids and proteins metabolism. 
Defects in intracellular signalling result in several metabolic 
abnormalities. Muscle is a major site of insulin resistance and changes 
in intracellular signalling pathway-depending on insulin initiate 
body protein loss [37]. Insulin resistance in skeletal muscle has been 
linked to fat accumulation, which could be significant in long term 
and could explain the fact that Ca inadequacy in early life may be 
most remarkable and predispose to and/or program individuals to an 
increased susceptibility to obesity and MS later in life [38,39].
Low Ca intake exacerbated established diabetic condition of 
obese strain of rats. It had been previously reported that rate of fatty 
acid uptake in muscle is markedly increased, while ability to oxidize 
fatty acids is decreased, in insulin-resistant skeletal muscle of animals 
with obesity and/or T2DM [40]. Both factors appear to be causal for 
accumulation of intracellular lipid intermediates, indicating that 
insulin resistance not only increases risk but also severity of T2DM. In 
this regard, the present report showed that all parameters of glucose 
and energy metabolism dysregulation, i.e., glucose and insulin levels, 
insulin resistance, dyslipemia, liver weight and excess of abdominal 
fat accumulation were higher in OLCa than in the other O rats. This 
effect may account for the great lean body mass reduction of OLCa 
[41]. Moreover, insulin resistance and obesity decreased HDL-Chol, 
which is associated with increased risk of atherosclerosis [42].
As mentioned, presence of obesity and insulin resistance could 
have produced certain degree of PTH resistance [43] that may be 
responsible for bone remodeling decrease as compared to control rats. 
However, among obese groups, low Ca availability led to OLCa rats 
to have a slight increase in bone turnover and subsequent decrease in 
bone mass.
Effect of the high ca diet in the interplay between bone 
and body fat in the regulation of glucose homeostasis
High Ca intake also affected glucose homeostasis in both strains of 
rats. WHCa evidenced signs of insulin resistance, i.e., hyperglycemia, 
elevated insulin levels and elevated HOMA-IR, but to a lesser degree 
than those observed in WLCa.
WHCa presented reduced Pi that may indicate a relative 
insufficiency of P intake. In this regard, it was previously suggested that 
an increase in Ca intake without the corresponding increase in P could 
increase risk of P insufficiency [44]. Several reports suggested that low 
bioavailability of P might affect glucose metabolism. In vitro studies 
demonstrated that pancreatic islets of phosphate-depleted rats had 
low ATP levels, elevated cytosolic Ca and impaired insulin secretion 
capacity [45]. The imbalance between extracellular and intracellular 
β cell Ca2+ pools results in diminished cellular responsiveness to 
insulin, increasing insulin resistance and glucose levels [35]. Clinical 
studies showed that low serum Pi were associated to insulin resistance 
and elevated blood glucose levels in healthy non-diabetic conditions, 
independently of body fat percentage [46]. Glucose intolerance and 
insulin resistance have been also documented in several diseases 
characterized for hypophosphatemia (hypophosphatemia rickets, 
adult-onset hypophosphatemia osteomalacia and renal Pi leak) [47].
Conversely, other authors have suggested that hyperglycemia 
per se could affect Pi status, directly or indirectly. High glucose 
levels induce depolarization of renal brush border membrane for Pi, 
leading to a decrease in intracellular Pi levels and hyperphosphaturia. 
However, hyperglycemia could also affect Pi status stimulating 
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peripheral Pi uptake by insulin [46,48]. Indeed, during hyperglycemic-
hyperinsulinemic conditions, high amounts of glucose enter into 
muscle and fat tissues (insulin-sensitive tissues); high Pi amount is 
required because glucose is metabolized by phosphorylation. This 
mechanism may lower serum Pi levels. Many investigators have 
found decreased concentrations of serum Pi in poorly regulated 
diabetic patients [49].
Adiposity was also reported to be inversely related to 
plasma Pi levels [45]. Low availability of Pi may hinders insulin 
phosphorylation having deleterious effects in phospholipids and 
hepatic fat accumulation [50]. A positive association was observed 
between low Pi levels and BW increase, which was largely attributed 
to increase in adipose tissue and impairment of in nitrogen retention 
[45]. The WHCa showed dyslipemia, i.e., hypercholesterolemia and 
hypertriglyceridemia, along with more severe changes in energy 
metabolism than those observed in WLCa, including increase in 
liver weight. These findings suggest the increase in lipid storage 
via concerted modulation of lipogenic and lipolytic processes 
(upregulation of lipogenesis). This effect could be responsible for the 
increased accumulation of body fat mass, especially abdominal fat 
pads, at expenses of a poor reduction in lean mass.
WHCa rats showed low Pi levels that along with high CTX levels, 
suggest a certain degree of 2°HPT. High levels of PTH promote Ca 
influx into adipocytes and enhances lipogenesis and obesity [51], 
associated to impairment in glucose tolerance and to decrease in 
insulin sensitivity [52]. Low availability of Pi could also affect energy 
metabolism via CNS through ATP production, in particular hepatic 
ATP [53].
Despite high CTX levels, WHCa showed low OCN and a decrease 
in OCN/b-ALP ratio that in presence of fat mass excess may account 
for impairment of osteoblast differentiation, which is reinforced by 
the lower bone mineral mass as compared to WNCa.
As mentioned before, Ca is important for insulin synthesis, 
secretion and functionality while P is important for insulin 
phosphorylation capacity and signalling. Insulin increases glucose 
uptake in muscle and fat, and inhibits lipolysis, contributing to the 
drop in glucose and insulin levels [54]. The OHCa presented Ca and 
Pi levels between reference range, suggesting a better control of Pi-
Ca homeostasis that may account for the improvement in glycemic 
indexes and fat metabolism. Indeed, according to literature lower 
liver weight and decrease in visceral fat mass accumulation without 
changes in lean mass may be the result of a better control of glucose 
metabolism and a low hepatic fat accumulation [55]. In spite, OHCa 
showed a low bone remodeling and low OCN release, which may 
explain the lack of association between glucose and OCN levels.
The weaknesses of this study using a growing rodent model 
would be relatively short duration of the experience. Further studies 
should be conducted to confirm whether same results are observed 
in adult animals. Another limitation might be that PTH and leptin, 
which could clarify presence of PTH and leptin resistance, were not 
measured. However, the strength was to evaluate and compare effect 
of habitual Ca intake on interrelationship between bone, pancreas 
and fat tissue in glucose homeostasis control, in normal physiological 
conditions and/versus animals with a predisposition to develop 
obesity and T2DM.
Conclusion
These evidence that bioavailability of Ca and/or Pi is associated 
to the relationship between bone turnover, adiposity and insulin 
resistance in glucose homeostasis control. However, effects on 
glucose homeostasis appear to differ in physiological conditions and 
in presence of metabolic abnormalities of energy dysregulation such 
as obesity and T2DM.
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